Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

BACKGROUND: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yamaguchi, Kensei, Sawaki, Akira, Doi, Toshihiko, Satoh, Taroh, Yamada, Yasuhide, Omuro, Yasushi, Nishina, Tomohiro, Boku, Narikazu, Chin, Keisho, Hamamoto, Yasuo, Takiuchi, Hiroya, Komatsu, Yoshito, Saji, Shigehira, Koizumi, Wasaburo, Miyata, Yoshinori, Sato, Atsushi, Baba, Eishi, Tamura, Takao, Abe, Takashi, Ohtsu, Atsushi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Japan 2012
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627028/
https://ncbi.nlm.nih.gov/pubmed/22782463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-012-0167-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller